Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial

Table 5 Number and percentage of children with a solicited injection-site reaction on days 0 to 4 in the safety set

	M-M-RvaxPro		VARIVAX
	IM group N= 374¹	SC group N= 376¹	IM group N= 374¹	SC group N= 376¹
	Number of subjects (%)²
Solicited injection-site reaction	58 (15.5)	81 (21.5)	57 (15.2)	85 (22.6)
Erythema	39 (10.4)	61 (16.2)	33 (8.8)	63 (16.8)
Pain	26 (7.0)	27 (7.2)	26 (7.0)	32 (8.5)
Swelling	7 (1.9)	20 (5.3)	12 (3.2)	18 (4.8)

(IM group, both vaccines administered by the intramuscular route; SC group, both vaccines administered by the subcutaneous route.)
¹Number of vaccinated subjects according to the protocol and the actual route of administration
² Number (and percentage) of subjects presenting the reaction at least once

ISSN: 1741-7015